Document Type : Original Research


1 Dept. of Pathology, Shahed University, Tehran, Iran

2 Dept. of Social Medicine, Shahed University, Tehran, Iran


Background and Aims: Immunohistochemical tests are one of the most important tests, which are under study to determine the prognosis of the cancers such as transitional cell carcinoma. By the time, flexible cystoscopy and urine cytology are the routine tests for following up the patients with transitional cell carcinoma, which are both operator dependent. On the other hand, cystoscopy is an invasive method, and urine cytology is a method with low sensitivity. The aim of this study was to determine CK20 in patients with transitional cell carcinoma of bladder and its relation with prognostic factors, which are the stage and the grade of the tumor.
Materials and Methods: Our study was done in Mostafa Khomeini Hospital from 2007 to 2010 on the 2001 to 2009 stored information files, included 53 patients diagnosed as transitional cell carcinoma of bladder (TCC) of different stages and grades that were underwent total cystectomy. Immunohistochemical staining was performed on tissue sections with specific CK20 antibody. Then the samples were studied by light microscope so positive and negative cases were identified.
Results: According to statistical analysis there were significant reverse relationship between CK20 and stage, and significant reverse relationship between CK20 and grade (P= 0.000).
Conclusion: Immunohistochemical study of patients with transitional cell carcinoma of bladder in order to identify CK20 can be a useful method to determine the prognosis of these patients.


  1. Cancer statistics 2009.A presentation from the American cancer society. [online] sep 2009.Available  from :  
  2. Fauci A, Braunwald E, Kasper D, Loscalzo J. Harrison’s principles of Internal Medicine .17th ed. New York:McGraw Hill;2008.
  3. Tanagho E, MC Aninch J. Smith's General Urology .17th ed. New York:McGraw Hill; 2008.
  4. Azizi F, Hatami H, Janghorbani M. Epidemiology and control of common disease in Iran. 2nd  ed. Tehran:Eshtiagh;2000.
  5. Vinay K, Abdul KA, Nelson F. Robins and Cotran pathologic basis of disease.7th ed. Philadelphia:Saunders;2004.
  6. Coulombe PA, Ma L, Yamada S, Wawersik M. Intermediate filaments at a glance. J Cell Sci 2002;114:4345-7.
  7. Eichner R, Bonitz P, Sun TT. Classification of epidermal keratins according to their immunoreactivity, isoelectric point, and mode of expression. J Cell Biol 1984;98:1388-96.
  8. Fuchs E, Weber K. Intermediate filaments: Structure, dynamics function, and disease. Ann Rev Biochem 1994;63:345-82.
  9. Rugg EL, Leigh IM. The keratins and their disorders. Am J Med Genet 2004;131:4-11.
  10. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell 2003;14: 2959-71.
  11. Alsheikh A, Mohmedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP Classification and CK20 expression in predicting the behavior of low-grade papillary urothelial tumors. Mod Pathol 2001;14:267-72.
  12. Morsi MI, Youssef AL, Hassouna ME, Elsedafi AS, Ghazal AA, ZaherER. Telomerase activity and CK20 in urine cells of bladder cancer patients. J Egypt Natl Canc Inst 2006;18(1):82-92.
  13. Parker DC, Folpe AL, Bell J, Oliva E, Young RH, Cohen C, et al. Potential utility of Uroplakin III , Thrombomodulin, High molecular weight CK20 in Urothelial carcinomas . AM J  Surg Pathol 2003;27(1):1-10.
  14. El-Salahi EM. Evaluation of cytokeratin 19 and CK20 and interleukin 6 in Egyptian Bladder cancer patients. Clin Biochem 2002; 35(8): 607-13.
  15. Bathia A, Dey P, Kumar Y, Gautam U, Kakkar N, Sinivasan R, et al. Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detectionof urothelial carcinoma. Cytopathology 2007;18(2):84-6.
  16. Melissourgos ND, Kastrinakis NG, Skolarikos A, Pappa M, Vassilakis G, Gorgoulis VG, et al. CK20 immunology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology.2005;66(3):536-41.
  17. Li HX, Li M, Li CL, Ma JH, Wanq MR, Roa J, et al. Immunocytology and cytokeratin 20 immunohistochemistry for urine cytologic detection of bladder cancer . Anal Quant Cytology . 2010:32(1):45-52.
  18. Ruchi Sirvastava,Vinod Kumar, Seema Aggarwal, Arati Bhatia. CK20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma .Diagn Cytopathol 2011 Jan 6. [Epub ahead of print]